TipRanks
Advertisement
Advertisement

RNXT Stock Latest News

RenovoRx price target raised to $14.50 from $14 at Ascendiant
The FlyRenovoRx price target raised to $14.50 from $14 at Ascendiant
27d ago
RNXT
RenovoRx publishes pharmacokinetic, pharmacodynamic data from TIGeR-PaC trial
PremiumThe Fly
RenovoRx publishes pharmacokinetic, pharmacodynamic data from TIGeR-PaC trial
1M ago
RNXT
RenovoRx regains compliance with Nasdaq
PremiumThe Fly
RenovoRx regains compliance with Nasdaq
1M ago
RNXT
RenovoRx Earnings Call: Record Growth, Rising Risks
PremiumCompany Announcements
RenovoRx Earnings Call: Record Growth, Rising Risks
1M ago
RNXT
RenovoRx Regains Nasdaq Compliance on Minimum Bid Price
PremiumCompany Announcements
RenovoRx Regains Nasdaq Compliance on Minimum Bid Price
1M ago
8K
RNXT
RenovoRx receives notice of allowance for new RenovoCath U.S. patent
PremiumThe FlyRenovoRx receives notice of allowance for new RenovoCath U.S. patent
1M ago
RNXT
Analyst Justin Walsh Reiterates Buy on RenovoRx After Strong 2Q26 Beat, Guidance Raise and Confirms $8 Price Target on TAMP Platform Momentum
Premium
Ratings
Analyst Justin Walsh Reiterates Buy on RenovoRx After Strong 2Q26 Beat, Guidance Raise and Confirms $8 Price Target on TAMP Platform Momentum
1M ago
RNXT
RenovoRx reports Q2 EPS (5c), consensus (8c)
Premium
The Fly
RenovoRx reports Q2 EPS (5c), consensus (8c)
1M ago
RNXT
RenovoRx raises FY26 revenue view to $3.75M-$4.25M from $3M-$4M
PremiumThe Fly
RenovoRx raises FY26 revenue view to $3.75M-$4.25M from $3M-$4M
1M ago
RNXT
RenovoRx completes enrollment in TIGeR-PaC trial
PremiumThe Fly
RenovoRx completes enrollment in TIGeR-PaC trial
1M ago
RNXT
RNXT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
RNXT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
RNXT
RenovoRx Highlights TAMP Platform in Upcoming Oncology Webinar
PremiumCompany Announcements
RenovoRx Highlights TAMP Platform in Upcoming Oncology Webinar
2M ago
8K
RNXT
RenovoRx Granted Extended Nasdaq Compliance Period Amid Listing Risk
PremiumCompany AnnouncementsRenovoRx Granted Extended Nasdaq Compliance Period Amid Listing Risk
3M ago
8K
RNXT
RenovoRx Stockholders Approve Directors and Equity Plan
Premium
Company Announcements
RenovoRx Stockholders Approve Directors and Equity Plan
3M ago
8K
RNXT
RenovoRx announces FDA Orphan Drug Designation for oxaliplatin
Premium
The Fly
RenovoRx announces FDA Orphan Drug Designation for oxaliplatin
4M ago
RNXT
RenovoRx announces pharmacokinetic data using TAMP platform
PremiumThe Fly
RenovoRx announces pharmacokinetic data using TAMP platform
4M ago
RNXT
RenovoRx Earnings Call Signals Commercial Inflection
PremiumCompany Announcements
RenovoRx Earnings Call Signals Commercial Inflection
4M ago
RNXT
RenovoRx reports Q1 adjusted EPS (8c), consensus (8c)
PremiumThe Fly
RenovoRx reports Q1 adjusted EPS (8c), consensus (8c)
4M ago
RNXT
RenovoRx sees FY26 revenue $3M-$4M, consensus $3.24M
PremiumThe Fly
RenovoRx sees FY26 revenue $3M-$4M, consensus $3.24M
4M ago
RNXT
RenovoRx files to sell 8.44M shares of common stock for holders
PremiumThe FlyRenovoRx files to sell 8.44M shares of common stock for holders
5M ago
RNXT
RenovoRx: Building Commercial Momentum Ahead of TIGeR-PaC Readout Supports Buy-Rated Risk‑Reward Profile
Premium
Ratings
RenovoRx: Building Commercial Momentum Ahead of TIGeR-PaC Readout Supports Buy-Rated Risk‑Reward Profile
6M ago
RNXT
RenovoRx secures Japanese patent allowance for targeted drug-delivery
Premium
The Fly
RenovoRx secures Japanese patent allowance for targeted drug-delivery
6M ago
RNXT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >